Vyleesi (Bremelanotide) Cost in Missouri: 2026 Pricing, Insurance, and Savings Guide

What Does Vyleesi Actually Cost at a Missouri Pharmacy?

The manufacturer list price for brand-name Vyleesi (bremelanotide 1.75 mg subcutaneous autoinjector) sits at approximately $1,200 per month in 2026. That figure holds relatively steady across Missouri retail chains and independent pharmacies because Palatin Technologies sets a single wholesale acquisition cost nationwide.

Retail Price Variation Across Missouri

Pricing differences between pharmacies in St. Louis, Kansas City, Springfield, and Columbia tend to be minor for brand-name Vyleesi. Unlike oral generics, which see meaningful variation between retail chains, single-source injectables maintain tighter price bands. Most Missouri patients filling brand Vyleesi without insurance will pay within $50 of that $1,200 mark regardless of location.

Why the Price Is High

Vyleesi remains a single-source branded product with no FDA-approved generic equivalent. The autoinjector delivery system adds manufacturing cost beyond the peptide itself. Palatin Technologies has not announced plans for a generic filing, and patent protections remain in place. That pricing context matters for patients weighing their options between brand, compounded, and savings-card-assisted routes.

The FDA approved bremelanotide in June 2019 based on the RECONNECT phase 3 trial program, which enrolled 1,247 premenopausal women with HSDD across two placebo-controlled studies. In RECONNECT, bremelanotide 1.75 mg produced a statistically significant increase in desire score (measured by the Female Sexual Function Index desire domain) and a significant decrease in distress (measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm) compared with placebo over 24 weeks [1].

Compounded Bremelanotide in Missouri: Legal, Cheaper, Different

Compounded bremelanotide is available in Missouri through licensed 503A pharmacies at roughly $140 per month. That is an 88% reduction from brand pricing. But compounded and brand are not identical products, and patients should understand the trade-offs.

What 503A Compounding Means

Under federal law (section 503A of the Food, Drug, and Cosmetic Act), a licensed compounding pharmacy can prepare bremelanotide from bulk pharmaceutical-grade powder when a patient holds a valid prescription. Missouri's Board of Pharmacy licenses and inspects these facilities. The compounded product is typically supplied as a multi-dose vial requiring the patient to draw up and inject using an insulin syringe, not the single-use autoinjector that comes with brand Vyleesi.

Trade-offs Worth Knowing

Compounded bremelanotide does not undergo the same FDA batch-testing, stability studies, or device-engineering review as the branded autoinjector. The FDA's prescribing information for Vyleesi specifies the 1.75 mg dose delivered via a single-use autoinjector with a defined pharmacokinetic profile [2]. Compounded vials rely on the compounding pharmacy's quality controls. For patients comfortable with manual subcutaneous injection technique and sourcing from a reputable 503A pharmacy with third-party potency testing, the cost savings are substantial.

Finding a Licensed 503A in Missouri

The Missouri Board of Pharmacy maintains a public database of licensed compounding pharmacies. Patients can verify a pharmacy's license status at the Board's website. A prescriber can also direct patients to specific 503A pharmacies with documented experience compounding peptide medications. Telehealth providers, including HealthRX, routinely connect Missouri patients with vetted compounding pharmacies.

Missouri Medicaid and Vyleesi: Not Covered

Missouri Medicaid does not cover Vyleesi. The state's preferred drug list excludes bremelanotide. There is no prior authorization pathway that would create an exception, because HSDD medications fall outside the categories Missouri Medicaid has elected to cover.

Why Medicaid Exclusion Matters in Missouri

Missouri expanded Medicaid eligibility in 2021, bringing over 300,000 additional residents into the program according to the Missouri Department of Social Services. Many of those newly eligible individuals are premenopausal women who could clinically qualify for Vyleesi. The Medicaid exclusion means these patients face full out-of-pocket cost for brand Vyleesi or must pursue compounded alternatives.

Dual-Eligible and Medicare Patients

Bremelanotide's FDA indication is limited to premenopausal women. Medicare Part D coverage is therefore rarely relevant, since most Medicare beneficiaries are postmenopausal. Dual-eligible patients (Medicaid plus Medicare) would not gain coverage through either program for this specific drug.

Commercial Insurance Coverage in Missouri

Coverage for Vyleesi among Missouri's commercial insurers is inconsistent. Some plans cover it with prior authorization; others exclude it entirely. The approval pathway, when it exists, typically requires documentation of HSDD diagnosis, failure or intolerance of at least one alternative intervention, and confirmation that the patient is premenopausal.

Plans That May Cover Vyleesi

Large employer-sponsored plans underwritten by UnitedHealthcare, Anthem Blue Cross Blue Shield, and Cigna have, in some benefit designs, included Vyleesi on specialty tiers with prior authorization. Coverage depends on the specific plan document, not just the insurer name. A "Cigna" plan through one Missouri employer may cover Vyleesi while the same carrier's plan at another employer excludes it.

How to Check Your Coverage

The most reliable method: call the number on the back of your insurance card and ask specifically whether bremelanotide (NDC for Vyleesi) is on formulary, what tier it occupies, and what prior authorization criteria apply. Pharmacy benefit managers (PBMs) such as Express Scripts, CVS Caremark, and OptumRx each maintain their own formulary decisions, and these change at least annually.

According to the American College of Obstetricians and Gynecologists (ACOG), HSDD is a recognized medical condition warranting treatment when it causes marked personal distress [3]. That clinical-society endorsement can strengthen prior authorization appeals.

Typical Cost with Insurance

When a commercial plan does cover Vyleesi, specialty-tier copays in Missouri often range from $75 to $250 per month. Plans with coinsurance rather than flat copays may require 20-30% of the drug's cost, pushing the patient portion to $240-$360 per month before any manufacturer copay assistance.

The Palatin Technologies Savings Card

Palatin Technologies offers a copay savings card for commercially insured patients. The card can reduce out-of-pocket costs to as low as $0 for eligible fills, depending on the specific program terms in effect during 2026.

Eligibility Requirements

The savings card is available to patients with commercial insurance. It is not valid for patients covered by Medicare, Medicaid, TRICARE, or any other government-funded program. Patients paying full cash price (uninsured) may also be ineligible for the copay card, though Palatin has periodically offered separate cash-pay discount programs.

How to Activate It

Patients can enroll through the Vyleesi website or receive a card through their prescribing clinician. The card is presented at the pharmacy alongside the insurance card. The PBM processes the insurance claim first, and the savings card covers part or all of the remaining copay.

Dr. Sheryl Kingsberg, a clinical psychologist at University Hospitals Cleveland Medical Center and principal investigator on the RECONNECT trials, has stated: "HSDD is a real medical condition that causes significant distress, and women deserve access to FDA-approved treatments without prohibitive cost barriers" [4].

Telehealth Access to Vyleesi in Missouri

Missouri permits telehealth prescribing of Vyleesi. A clinician licensed in Missouri can evaluate a patient via video visit, diagnose HSDD, and prescribe bremelanotide without requiring an in-person exam. This is particularly relevant for patients in rural Missouri counties where sexual-medicine specialists may not practice locally.

What a Telehealth Visit Looks Like

The clinician takes a sexual health history, screens for HSDD using validated instruments such as the Decreased Sexual Desire Screener (DSDS), rules out other causes of low desire (medication side effects, relationship factors, mood disorders, hormonal deficiency), and reviews contraindications. If bremelanotide is appropriate, the prescription goes to the patient's chosen pharmacy.

Missouri-Specific Telehealth Rules

Missouri enacted SB 52 in 2021, which made pandemic-era telehealth flexibilities permanent. Prescribers must hold an active Missouri medical license. The state does not require a prior in-person visit before a telehealth prescription for Vyleesi. Interstate telehealth may be available through providers participating in interstate medical licensure compacts.

The Endocrine Society's clinical practice guidelines recognize that sexual dysfunction in women is multifactorial and that pharmacotherapy may be appropriate when psychosocial interventions alone are insufficient [5].

Practical Strategies to Reduce Cost

Missouri patients have several actionable pathways to lower their out-of-pocket Vyleesi spending beyond the options already described.

Dose Optimization

Vyleesi is dosed as needed, not daily. A patient who uses the medication four times per month will spend half what a patient using it eight times monthly spends. Working with a prescriber to clarify realistic usage frequency before filling a prescription prevents waste. The FDA label caps dosing at 8 uses per month and no more than one dose in 24 hours [2].

Specialty Pharmacy Shopping

Not all specialty pharmacies charge the same dispensing fee or apply the same markup. Patients should request price quotes from at least two specialty pharmacies before filling. Some mail-order specialty pharmacies offer lower pricing than brick-and-mortar locations.

Patient Assistance Programs

Patients with household income below 400% of the federal poverty level may qualify for manufacturer-sponsored patient assistance programs (PAPs). These programs typically provide the drug at no cost but require income documentation and proof that the patient lacks adequate insurance coverage for the medication.

Compounding as the Default for Uninsured Patients

For Missouri patients without commercial insurance, compounded bremelanotide at approximately $140 per month from a 503A pharmacy is the most cost-effective route. That figure represents roughly 12% of the brand price. A patient using bremelanotide four times monthly through a compounded vial pays approximately $35 per use.

Safety Considerations That Affect Cost Decisions

Cost-driven decisions should not override safety. Bremelanotide carries specific contraindications and monitoring requirements that apply regardless of whether a patient uses brand or compounded product.

Blood Pressure Effects

The RECONNECT trials documented a transient increase in systolic blood pressure of approximately 2-3 mmHg following bremelanotide injection, with peak effect at 2-3 hours post-dose [1]. Bremelanotide is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease. The FDA label recommends blood pressure measurement before initiating therapy [2].

Nausea Management

Nausea was the most common adverse event in RECONNECT, reported by 40.0% of bremelanotide-treated participants versus 1.3% on placebo [1]. Most nausea episodes were mild and decreased with repeated dosing. Patients who discontinue due to nausea lose their financial investment in unused doses. Starting with a plan for anti-nausea management (e.g., ondansetron pretreatment) can prevent costly early discontinuation.

Melanocyte Effects

Bremelanotide is a melanocortin receptor agonist. Focal hyperpigmentation, particularly of the face and gingiva, occurred in 1% of patients in clinical trials. The FDA prescribing information notes this effect may not resolve after discontinuation [2]. Patients should be counseled on this possibility before committing financially to ongoing therapy.

Dr. Anita Clayton, Professor of Psychiatry and Neurobehavioral Sciences at the University of Virginia and co-investigator on the RECONNECT program, has noted: "The nausea seen with bremelanotide tends to attenuate over time, and most women who continue therapy find the benefit-to-side-effect ratio acceptable after the first few uses" [6].

How Missouri Compares to Neighboring States

Brand Vyleesi pricing is essentially identical across Missouri, Kansas, Illinois, Iowa, and Arkansas because the manufacturer sets a national list price. The meaningful differences are in Medicaid coverage and compounding pharmacy availability.

Kansas, like Missouri, does not cover Vyleesi under Medicaid. Illinois has a slightly broader formulary review process but has also excluded bremelanotide as of 2026. None of Missouri's bordering states currently provide Medicaid coverage for Vyleesi. Compounded bremelanotide availability through 503A pharmacies is permitted in all neighboring states, though pricing may differ by pharmacy.